Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas

Next Previous
Trial Profile

A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Indimitecan (Primary) ; Indotecan (Primary)
  • Indications Adenocarcinoma; Adrenocortical carcinoma; Bladder cancer; Breast cancer; Colorectal cancer; Head and neck cancer; Hodgkin's disease; Lymphoma; Male breast cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Parotid cancer; Renal cell carcinoma; Sarcoma; Small cell lung cancer; Solid tumours; Thyroid cancer; Vulvovaginal cancer
  • Focus Adverse reactions; First in man

Most Recent Events

  • 22 Jun 2017 Status changed from active, no longer recruiting to completed.
  • 22 Jun 2017 Status changed from active, no longer recruiting to completed.
  • 02 Jun 2017 Results (n=34) assessing safety and tolerability of LMP776 in patients with with relapsed solid tumors and lymphomas, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top